We understand the CBD market and your obligations.
As a leading provider of Pharmacovigilance and Regulatory Affairs services in the EEA and beyond, we provide an end-to-end service solution for companies developing medicinal products in the fast-growing cannabinoid derivative area, from clinical development and core risk management planning, through to all your registration, post-marketing and life-cycle maintenance needs.
Cannabinoid based medicinal products are subject to the same obligations as other pharmaceutical products, including clinical trials. Our experience with existing cannabinoid medicines, as well as with advanced therapies and biotech products, makes us ideally suited to provide expert guidance for companies developing and manufacturing cannabinoid-derived medicines.
No time to waste in growing market.
For further information on getting medical cannabis products into European markets safely, effectively and within the regulations contact [email protected] or use the form below.
Arriello currently services multiple centrally approved cannabinoid-based products and can provide expert, tailored solutions in the following phases:
Country by country guidance on medical cannabis in Europe and the CIS regions.
The market for medical cannabis is growing fast around the world and the UN commission have just reclassified cannabis in line with World Health Organization recommendations, yet despite the idea of a harmonized European market there are in fact multiple variations and requirements at the national level that can make it unclear… without the brand new Arriello guide!
Put together by Director of Drug Safety, Peter Kohut and MENA PV specialist Ibrahim Said Abdeldayem, the Arriello guide to marketing medical cannabis in Europe illustrates the situation across this and the adjacent CIS region with details for each country and links to specific regulations.